Skip Navigation
Skip to contents

J Pathol Transl Med : Journal of Pathology and Translational Medicine

OPEN ACCESS
SEARCH
Search

Search

Page Path
HOME > Search
3 "Gene amplification"
Filter
Filter
Article category
Keywords
Publication year
Authors
Funded articles
Original Articles
HER2 Status and Its Heterogeneity in Gastric Carcinoma of Vietnamese Patient
Dang Anh Thu Phan, Vu Thien Nguyen, Thi Ngoc Ha Hua, Quoc Dat Ngo, Thi Phuong Thao Doan, Sao Trung Nguyen, Anh Tu Thai, Van Thanh Nguyen
J Pathol Transl Med. 2017;51(4):396-402.   Published online June 19, 2017
DOI: https://doi.org/10.4132/jptm.2017.04.24
  • 8,000 View
  • 139 Download
  • 8 Web of Science
  • 7 Crossref
AbstractAbstract PDF
Background
Human epidermal growth factor receptor 2 (HER2) is related to the pathogenesis and poor outcome of numerous types of carcinomas, including gastric carcinoma. Gastric cancer patients with HER2 positivity have become potential candidates for targeted therapy with trastuzumab.
Methods
We investigated 208 gastric cancer specimens using immunohistochemistry (IHC), fluorescence in situ hybridization and dual in situ hybridization (ISH). We also investigated the concordance between IHC and ISH. The correlation between HER2 status and various clinicopathological findings was also investigated.
Results
In total, 15.9% (33/208) and 24.5% (51/208) of gastric cancers showed HER2 gene amplification and protein overexpression, respectively. A high level of concordance between ISH and IHC analyses (91.3%, κ = 0.76) was found. A significant correlation between HER2 status and intestinal-type (p < .05) and differentiated carcinomas (p < .05) was also noted. The HER2 heterogeneity was high in gastric cancers; we found 68.8% phenotypic heterogeneity and 57.6% genotypic heterogeneity. Heterogeneity in HER2 protein expression and gene amplification showed a close association with diffuse histologic type and IHC 2+.
Conclusions
HER2 protein overexpression and gene amplification were detected in 24.5% and 15.9% of gastric cancer specimens, respectively. Intestinal-type showed a higher level of HER2 protein overexpression and gene amplification than diffuse type. HER2 status also showed a significant relationship with well- and moderately-differentiated carcinomas. The ratio of phenotypic and genotypic heterogeneity of HER2 was high in gastric carcinomas and was associated with HER2 IHC 2+ and diffuse histologic type.

Citations

Citations to this article as recorded by  
  • Identifying HER2 from serum‐derived exosomes in advanced gastric cancer as a promising biomarker for assessing tissue HER2 status and predicting the efficacy of trastuzumab‐based therapy
    Qian Li, Minzhi Lv, Lihua Lv, Nida Cao, Aiguang Zhao, Jiayan Chen, Xi Tang, Rongkui Luo, Shan Yu, Yan Zhou, Yuehong Cui, Wei Guo, Tianshu Liu
    Cancer Medicine.2023; 12(4): 4110.     CrossRef
  • A study of human epidermal growth factor receptor 2 overexpression by immunohistochemistry in patients with gastric adenocarcinoma
    Rafid A. Abood, Saad Alomar, Sawsan S. Alharoon
    Journal of Public Health in Africa.2023;[Epub]     CrossRef
  • Receptor Tyrosine Kinases Amplified in Diffuse-Type Gastric Carcinoma: Potential Targeted Therapies and Novel Downstream Effectors
    Hideki Yamaguchi, Yuko Nagamura, Makoto Miyazaki
    Cancers.2022; 14(15): 3750.     CrossRef
  • Cell differentiation trajectory predicts patient potential immunotherapy response and prognosis in gastric cancer
    Renshen Xiang, Yuping Rong, Yuhang Ge, Wei Song, Jun Ren, Tao Fu
    Aging.2021; 13(4): 5928.     CrossRef
  • Identification of stem cell-related subtypes and risk scoring for gastric cancer based on stem genomic profiling
    Renshen Xiang, Wei Song, Jun Ren, Jing Wu, Jincheng Fu, Tao Fu
    Stem Cell Research & Therapy.2021;[Epub]     CrossRef
  • Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer
    Yoshie Kobayashi, Seung-Oe Lim, Hirohito Yamaguchi
    Seminars in Cancer Biology.2020; 65: 51.     CrossRef
  • Blockade of ITGA2 Induces Apoptosis and Inhibits Cell Migration in Gastric Cancer
    Yu-Chang Chuang, Hsin-Yi Wu, Yu-Ling Lin, Shey-Cherng Tzou, Cheng-Hsun Chuang, Ting-Yan Jian, Pin-Rong Chen, Yuan-Ching Chang, Chi-Hsin Lin, Tse-Hung Huang, Chao-Ching Wang, Yi-Lin Chan, Kuang-Wen Liao
    Biological Procedures Online.2018;[Epub]     CrossRef
EGFR Gene Amplification and Protein Expression in Invasive Ductal Carcinoma of the Breast
Won Hwangbo, Jeong Hyeon Lee, Sangjeong Ahn, Seojin Kim, Kyong Hwa Park, Chul Hwan Kim, Insun Kim
Korean J Pathol. 2013;47(2):107-115.   Published online April 24, 2013
DOI: https://doi.org/10.4132/KoreanJPathol.2013.47.2.107
  • 11,190 View
  • 66 Download
  • 14 Crossref
AbstractAbstract PDF
Background

The epidermal growth factor receptor (EGFR) is a surrogate marker for basal-like breast cancer. A recent study suggested that EGFR may be used as a target for breast cancer treatment.

Methods

A total of 706 invasive ductal carcinomas (IDC) of the breast were immunophenotyped, and 82 cases with EGFR protein expression were studied for EGFR gene amplification.

Results

EGFR protein was expressed in 121 of 706 IDCs (17.1%); 5.9% were of luminal type, 25.3% of epidermal growth factor receptor 2 (HER-2) type, and 79.3% of basal-like tumors. EGFR gene amplification and high polysomy (fluorescent in situ hybridization [FISH]-positive) were found in 18 of 82 cases (22.0%); 41.2% of the HER-2+, EGFR+, cytokeratin 5/6- (CK5/6-) group, 11.2% of the HER-2-, EGFR+, CK5/6- group, and 19.1% of the HER-2-, EGFR+, CK5/6+ group. FISH-positive cases were detected in 8.3% of the EGFR protein 1+ expression cases, 15.9% of 2+ expression cases, and 38.5% of 3+ expression cases. In group 2, the tumors had a high Ki-67 labeling (>60%), but the patients showed better disease-free survival than those with tumors that co-expressed HER-2 or CK5/6.

Conclusions

EGFR-directed therapy can be considered in breast cancer patients with EGFR protein overexpression and gene amplification, and its therapeutic implication should be determined in HER-2 type breast cancer patients.

Citations

Citations to this article as recorded by  
  • Identification of a cross-talk between EGFR and Wnt/beta-catenin signaling pathways in HepG2 liver cancer cells
    Gurjinder Singh, Md Mehedi Hossain, Aadil Qadir Bhat, Mir Owais Ayaz, Nasima Bano, Rafiqa Eachkoti, Mohd Jamal Dar
    Cellular Signalling.2021; 79: 109885.     CrossRef
  • Blocking c-MET/ERBB1 Axis Prevents Brain Metastasis in ERBB2+ Breast Cancer
    Shailendra K. Gautam, Ranjana K. Kanchan, Jawed A. Siddiqui, Shailendra K. Maurya, Sanchita Rauth, Naveenkumar Perumal, Pranita Atri, Ramakanth C. Venkata, Kavita Mallya, Sameer Mirza, Moorthy P. Ponnusamy, Vimla Band, Sidharth Mahapatra, Maneesh Jain, Su
    Cancers.2020; 12(10): 2838.     CrossRef
  • Evaluation of lapatinib cytotoxicity and genotoxicity on MDA-MB-231 breast cancer cell line
    Mona A.M. Abo-Zeid, Mahmoud T. Abo-Elfadl, Amira M. Gamal-Eldeen
    Environmental Toxicology and Pharmacology.2019; 71: 103207.     CrossRef
  • Improved characterization of the relationship between long intergenic non‐coding RNA Linc00152 and the occurrence and development of malignancies
    Jiasheng Xu, Jingjing Guo, Yangkai Jiang, Yujun Liu, Kaili Liao, Zhonghua Fu, Zhenfang Xiong
    Cancer Medicine.2019; 8(10): 4722.     CrossRef
  • Relationship between EGFR expression and subcellular localization with cancer development and clinical outcome
    Ge Yan, Mohamed E.M. Saeed, Sebastian Foersch, Jose Schneider, Wilfried Roth, Thomas Efferth
    Oncotarget.2019; 10(20): 1918.     CrossRef
  • A novel matrine derivative WM622 inhibits hepatocellular carcinoma by inhibiting PI3K/AKT signaling pathways
    Xiao Sun, Xiao-bin Zhuo, Yi-ping Hu, Xuan Zheng, Qing-jie Zhao
    Molecular and Cellular Biochemistry.2018; 449(1-2): 47.     CrossRef
  • lncRNA LINC00152 knockdown had effects to suppress biological activity of lung cancer via EGFR/PI3K/AKT pathway
    Yan Zhang, Cheng Xiang, Yuling Wang, Yuanyuan Duan, Ci Liu, Yongli Jin, Yajing Zhang
    Biomedicine & Pharmacotherapy.2017; 94: 644.     CrossRef
  • Copy Number Profiling of MammaPrint™ Genes Reveals Association with the Prognosis of Breast Cancer Patients
    Areej Fatima, Fomaz Tariq, Muhammad Faraz Arshad Malik, Muhammad Qasim, Farhan Haq
    Journal of Breast Cancer.2017; 20(3): 246.     CrossRef
  • Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
    Malgorzata Banys-Paluchowski, Isabell Witzel, Sabine Riethdorf, Brigitte Rack, Wolfgang Janni, Peter A. Fasching, Erich-Franz Solomayer, Bahriye Aktas, Sabine Kasimir-Bauer, Klaus Pantel, Tanja Fehm, Volkmar Müller
    Scientific Reports.2017;[Epub]     CrossRef
  • EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib
    James P. De Andrade, Jung M. Park, Vivian W. Gu, George W. Woodfield, Mikhail V. Kulak, Allison W. Lorenzen, Vincent T. Wu, Sarah E. Van Dorin, Philip M. Spanheimer, Ronald J. Weigel
    Molecular Cancer Therapeutics.2016; 15(3): 503.     CrossRef
  • Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer
    H J Lee, A N Seo, E J Kim, M H Jang, Y J Kim, J H Kim, S-W Kim, H S Ryu, I A Park, S-A Im, G Gong, K H Jung, H J Kim, S Y Park
    British Journal of Cancer.2015; 112(1): 103.     CrossRef
  • Epidermal growth factor receptor protein overexpression and gene amplification are associated with aggressive biological behaviors of esophageal squamous cell carcinoma
    GANG LIN, XIAO-JIANG SUN, QIAN-BO HAN, ZHUN WANG, YA-PING XU, JIA-LEI GU, WEI WU, GU ZHANG, JIN-LIN HU, WEN-YONG SUN, WEI-MIN MAO
    Oncology Letters.2015; 10(2): 901.     CrossRef
  • Immunohistochemical Classification of Primary and Secondary Glioblastomas
    Kyu Sang Lee, Gheeyoung Choe, Kyung Han Nam, An Na Seo, Sumi Yun, Kyung Ju Kim, Hwa Jin Cho, Sung Hye Park
    Korean Journal of Pathology.2013; 47(6): 541.     CrossRef
  • A Comparison of Tumor Biology in Primary Ductal CarcinomaIn SituRecurring as Invasive Carcinoma versus a NewIn Situ
    Wenjing Zhou, Christine Johansson, Karin Jirström, Anita Ringberg, Carl Blomqvist, Rose-Marie Amini, Marie-Louise Fjallskog, Fredrik Wärnberg
    International Journal of Breast Cancer.2013; 2013: 1.     CrossRef
Expression of c-Met Is Different along the Location and Associated with Lymph Node Metastasis of Head and Neck Carcinoma
Ji-Young Choe, Ji Yun Yun, Soo-Jeong Nam, Ji Eun Kim
Korean J Pathol. 2012;46(6):515-522.   Published online December 26, 2012
DOI: https://doi.org/10.4132/KoreanJPathol.2012.46.6.515
  • 6,380 View
  • 44 Download
  • 18 Crossref
AbstractAbstract PDF
Background

Activation of the c-Met pathway is involved in cancer progression and the prognosis. We aimed to identify any association of c-Met protein expression with a number of clinicopathologic variables including infection of human papillomavirus and Epstein-Barr virus (EBV) in head and neck carcinomas (HNCa).

Methods

Eighty-two cases were enrolled in this study. Expression of c-Met and p16 was investigated immunohistochemically. EBV was detected by in situ hybridization and amplification of the c-Met gene by fluorescence in situ hybridization.

Results

The c-Met protein was expressed in 41.5% (34/82), and gene amplification was found in 1.4% (1/71). High expression of c-Met was associated with the primary location of the tumor; the hypopharynx showed the highest expression, followed by the oral cavity, larynx, and nasal cavity. Squamous cell carcinoma expressed c-Met more frequently than undifferentiated carcinoma. Also, p16 immunoreactivity or EBV infection was associated with the tumor location and well-differentiated histologic type, but were not linked to c-Met expression. The patients with positive c-Met expression showed frequent lymph node metastasis.

Conclusions

Activation of the c-Met pathway might be involved in a subset of HNCa. Cases showing positive c-Met expression should be carefully monitored because of the high probability of lymph node metastasis.

Citations

Citations to this article as recorded by  
  • c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy
    Chakrabhavi Dhananjaya Mohan, Muthu K Shanmugam, Siddegowda Gopalapura Shivanne Gowda, Arunachalam Chinnathambi, Kanchugarakoppal S. Rangappa, Gautam Sethi
    Phytomedicine.2024; 128: 155379.     CrossRef
  • Nadir paranazal sinüs kanserlerinde yeni tanımlanan reseptör tirozin kinaz mutasyonları ve potansiyel fonksiyonel etkileri
    Bakiye GÖKER BAGCA, Sercan GÖDE, Göksel TURHAL, Neslihan Pınar ÖZATEŞ, Ali VERAL, Cumhur GÜNDÜZ, Çığır Biray AVCI
    Ege Tıp Dergisi.2023; 62(1): 139.     CrossRef
  • The Emerging Role of c-Met in Carcinogenesis and Clinical Implications as a Possible Therapeutic Target
    Antonio Faiella, Ferdinando Riccardi, Giacomo Cartenì, Martina Chiurazzi, Livia Onofrio, Rengyun Liu
    Journal of Oncology.2022; 2022: 1.     CrossRef
  • NK4 Regulates Laryngeal Squamous Cell Carcinoma Cell Properties and Inhibits Tumorigenicity by Modulating the DKK1/Wnt/β-Catenin Axis
    Shoukai Zhang, Hulai Wei, Xiaoqin Ha, Yueyu Zhang, Yufen Guo
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Epstein-Barr Virus-Associated Carcinoma of the Larynx: A Systematic Review with Meta-Analysis
    Marcos Antonio Pereira de Lima, Álife Diêgo Lima Silva, Antônio Carlos Silva do Nascimento Filho, Thiago Lima Cordeiro, João Pedro de Souza Bezerra, Maria Aline Barroso Rocha, Sally de França Lacerda Pinheiro, Roberto Flávio Fontenelle Pinheiro Junior, Ma
    Pathogens.2021; 10(11): 1429.     CrossRef
  • The roles of PTEN, cMET, and p16 in resistance to cetuximab in head and neck squamous cell carcinoma
    Alexandre A. B. A. da Costa, Felipe D’Almeida Costa, Daniel Vilarim Araújo, Marcos Pedro Guedes Camandaroba, Victor Hugo Fonseca de Jesus, Audrey Oliveira, Ana Caroline Fonseca Alves, Carlos Stecca, Larissa Machado, Andrea Cruz Feraz de Oliveira, Thiago B
    Medical Oncology.2019;[Epub]     CrossRef
  • Role of c‐Met expression on prognosis of head and neck cancer: A literature review and meta‐analysis
    Lei Li, Zhijun Sun, Xin Huang, Xiao Li, Lihua Sun, Lei Zhang, Xiaodan Zhang, Longwei Ye, Jie Yuan, Limin Mao, Guolin Li
    Head & Neck.2019; 41(6): 1999.     CrossRef
  • MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation
    Lisa Pei Chu, Debra Franck, Christine A. Parachoniak, Jeffrey P. Gregg, Michael G. Moore, D. Gregory Farwell, Shyam Rao, Andreas M. Heilmann, Rachel L. Erlich, Jeffrey S. Ross, Vincent A. Miller, Siraj Ali, Jonathan W. Riess
    The Oncologist.2019; 24(10): 1305.     CrossRef
  • Understanding c-MET signalling in squamous cell carcinoma of the head & neck
    P. Szturz, E. Raymond, C. Abitbol, S. Albert, A. de Gramont, S. Faivre
    Critical Reviews in Oncology/Hematology.2017; 111: 39.     CrossRef
  • Prognostic value of c-MET in head and neck cancer: A systematic review and meta-analysis of aggregate data
    Petr Szturz, Marie Budíková, Jan B. Vermorken, Ivana Horová, Břetislav Gál, Eric Raymond, Armand de Gramont, Sandrine Faivre
    Oral Oncology.2017; 74: 68.     CrossRef
  • Activated HGF-c-Met Axis in Head and Neck Cancer
    Levi Arnold, Jonathan Enders, Sufi Thomas
    Cancers.2017; 9(12): 169.     CrossRef
  • Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review
    Jung Han Kim, Bum Jun Kim, Hyeong Su Kim
    Oncotarget.2017; 8(68): 113120.     CrossRef
  • High expression of c‑Met and EGFR is associated with poor survival of patients with glottic laryngeal squamous cell carcinoma
    Mei Jiang, Hui Zhang, He Xiao, Zhimin Zhang, Dan Que, Jia Luo, Jian Li, Bijing Mao, Yuanyuan Chen, Meilin Lan, Ge Wang, Hualiang Xiao
    Oncology Letters.2017;[Epub]     CrossRef
  • Profiling of cMET and HER Family Receptor Expression in Pancreatic Ductal Adenocarcinomas and Corresponding Lymph Node Metastasis to Assess Relevant Pathways for Targeted Therapies
    Alexander Muckenhuber, Galina Babitzki, Marlene Thomas, Gabriele Hölzlwimmer, Magdalena Zajac, Moritz Jesinghaus, Frank Bergmann, Jens Werner, Albrecht Stenzinger, Wilko Weichert
    Pancreas.2016; 45(8): 1167.     CrossRef
  • Absent and abundant MET immunoreactivity is associated with poor prognosis of patients with oral and oropharyngeal squamous cell carcinoma
    Maria J. De Herdt, Stefan M. Willems, Berdine van der Steen, Rob Noorlag, Esther I. Verhoef, Geert J.L.H. van Leenders, Robert J.J. van Es, Senada Koljenović, Robert J. Baatenburg de Jong, Leendert H.J. Looijenga
    Oncotarget.2016; 7(11): 13167.     CrossRef
  • Biological, diagnostic and therapeutic relevance of the MET receptor signaling in head and neck cancer
    Lluís Nisa, Daniel Matthias Aebersold, Roland Giger, Yitzhak Zimmer, Michaela Medová
    Pharmacology & Therapeutics.2014; 143(3): 337.     CrossRef
  • Frequent hepatocyte growth factor overexpression and low frequency of c-Met gene amplification in human papillomavirus–negative tonsillar squamous cell carcinoma and their prognostic significances
    Mi Jung Kwon, Dong Hoon Kim, Hye-Rim Park, Hyung Sik Shin, Ji Hyun Kwon, Dong Jin Lee, Jin Hwan Kim, Seong Jin Cho, Eun Sook Nam
    Human Pathology.2014; 45(7): 1327.     CrossRef
  • Distinct c-Met activation mechanisms induce cell rounding or invasion through pathways involving integrins, RhoA and HIP1
    Anja Mai, Ghaffar Muharram, Rachel Barrow-McGee, Habib Baghirov, Juha Rantala, Stéphanie Kermorgant, Johanna Ivaska
    Journal of Cell Science.2014; 127(9): 1938.     CrossRef

J Pathol Transl Med : Journal of Pathology and Translational Medicine